United Kingdom · Question · Written question
UIN 94872
Puberty Suppressing Hormones: Gender Dysphoria
Original
Introduced
26 November 2025
Last action
17 December 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
17 December 2025
Summary
To ask the Secretary of State for Health and Social Care, what evidence NICE has identified as the basis for its clinical assessment of puberty blockers for gender dysphoria; and whether NICE has undertaken (a) scoping and (b) evaluation exercises since 2
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
26 November 2025
Written question
To ask the Secretary of State for Health and Social Care, what evidence NICE has identified as the basis for its clinical assessment of puberty blockers for gender dysphoria; and whether NICE has undertaken (a) scoping and (b) evaluation exercises since 2
Source: Commons
17 December 2025
Answer
The National Institute for Health and Care Excellence (NICE) has not developed guidance on, or made a clinical assessment of, puberty blockers for gender dysphoria. In 2020, NICE developed two evidence summaries:Gonadotrophin releasing hormone analogues f...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-11-26/94872
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1857393
- uk · wq-1857393 · source updated 17 December 2025